Drugs / LS11
LS11
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00716469 | Jul 2008 → Jul 2012 | neurofibroma | Children's Hospital of Philadelphia | Terminated | No outcome recorded |
| Phase 1 | NCT00028405 | Nov 2001 → Dec 2002 | breast cancer, head and neck cancer, oral cavity cancer, rectal cancer +1 | Light Sciences LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00409214 | Nov 2006 → Feb 2008 | anaplastic astrocytoma, glioblastoma | Light Sciences Oncology | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LS 11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00028405 ↗ |
| Known as | talaporfin sodium | “LS11 (talaporfin sodium)” NCT00409214 ↗ |
| Known as | Taporfin Sodium | “LS 11(Taporfin Sodium)” NCT00028405 ↗ |
| Modality | Other / unclassified | “a systemically administered light-activated drug (LS11)” NCT00409214 ↗ |
| Route | Intravenous | “a single, intravenous administration of an investigational drug” NCT00028405 ↗ |